These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 26112672)

  • 1. Cellular backpackers deliver lymphoma drugs.
    Cancer Discov; 2015 Aug; 5(8):786-7. PubMed ID: 26112672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells.
    Huang B; Abraham WD; Zheng Y; Bustamante López SC; Luo SS; Irvine DJ
    Sci Transl Med; 2015 Jun; 7(291):291ra94. PubMed ID: 26062846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescription for a pharmacyte.
    Hubbell JA
    Sci Transl Med; 2015 Jun; 7(291):291fs23. PubMed ID: 26062842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
    J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
    Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
    J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matching of chemotherapy to mouse strain and lymphoid tumor type to prevent tumor-induced suppression of specific T- and B-cell functions.
    Faanes RB; Merluzzi VJ; Williams N; Tarnowski GS; Ralph P
    Cancer Res; 1979 Nov; 39(11):4564-74. PubMed ID: 315269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study.
    Zaleskis G; Ho RL; Diegelman P; Maccubbin D; Ujházy P; Mihich E; Ehrke MJ
    Oncol Res; 1994; 6(4-5):183-94. PubMed ID: 7841541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
    Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting tumor cells through chitosan-folate modified microcapsules loaded with camptothecin.
    Galbiati A; Tabolacci C; Morozzo Della Rocca B; Mattioli P; Beninati S; Paradossi G; Desideri A
    Bioconjug Chem; 2011 Jun; 22(6):1066-72. PubMed ID: 21545180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
    Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
    Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designer combination therapy for cancer.
    Lane D
    Nat Biotechnol; 2006 Feb; 24(2):163-4. PubMed ID: 16465160
    [No Abstract]   [Full Text] [Related]  

  • 12. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
    Diddens H; Niethammer D; Jackson RC
    Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prodrug nanoassembly entrapping drugs as a tumor-targeted delivery system.
    Yuan Z; Yi X; Zhang J; Cheng S; Zhuo R; Li F
    Chem Commun (Camb); 2013 Jan; 49(8):801-3. PubMed ID: 23235958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel.
    Gupta S; Wulf G; Henjakovic M; Koepsell H; Burckhardt G; Hagos Y
    J Pharmacol Exp Ther; 2012 Apr; 341(1):16-23. PubMed ID: 22202118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
    Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
    Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.
    Wang W; Ghandi A; Liebes L; Louie SG; Hofman FM; Schönthal AH; Chen TC
    J Neurosurg; 2011 Mar; 114(3):689-94. PubMed ID: 20415520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.
    Ramsay EC; Anantha M; Zastre J; Meijs M; Zonderhuis J; Strutt D; Webb MS; Waterhouse D; Bally MB
    Clin Cancer Res; 2008 Feb; 14(4):1208-17. PubMed ID: 18281556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
    Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G
    Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.
    Maitani Y; Saito H; Seishi Y; Iwase Y; Yamauchi T; Higashiyama K; Sugino T
    J Drug Target; 2012 Dec; 20(10):873-82. PubMed ID: 23050928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.